GB1242211A - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- GB1242211A GB1242211A GB36270/67A GB3627067A GB1242211A GB 1242211 A GB1242211 A GB 1242211A GB 36270/67 A GB36270/67 A GB 36270/67A GB 3627067 A GB3627067 A GB 3627067A GB 1242211 A GB1242211 A GB 1242211A
- Authority
- GB
- United Kingdom
- Prior art keywords
- medicament
- particle size
- carrier
- powder
- effective particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 7
- 239000002245 particle Substances 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 5
- 239000000843 powder Substances 0.000 abstract 4
- 239000007787 solid Substances 0.000 abstract 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 abstract 1
- ZOLBALGTFCCTJF-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC=C(O)C(O)=C1.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 ZOLBALGTFCCTJF-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229930182555 Penicillin Natural products 0.000 abstract 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 239000000150 Sympathomimetic Substances 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 239000004098 Tetracycline Substances 0.000 abstract 1
- 229960004308 acetylcysteine Drugs 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000002804 anti-anaphylactic effect Effects 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 229960002179 ephedrine Drugs 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract 1
- 229960001317 isoprenaline Drugs 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000510 mucolytic effect Effects 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 229940049954 penicillin Drugs 0.000 abstract 1
- 229920003023 plastic Polymers 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 230000001975 sympathomimetic effect Effects 0.000 abstract 1
- 229960002180 tetracycline Drugs 0.000 abstract 1
- 229930101283 tetracycline Natural products 0.000 abstract 1
- 235000019364 tetracycline Nutrition 0.000 abstract 1
- 150000003522 tetracyclines Chemical class 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fastening Of Light Sources Or Lamp Holders (AREA)
Abstract
1,242,211. Powder compositions for inhalation. FISONS PHARMACEUTICALS Ltd. 23 July, 1968 [8 Aug., 1967], No. 36270/67. Heading A5B. A pharmaceutical powder composition for inhalation comprises a mixture of a solid finely divided medicament having an effective particle size in the range 0.01 to 10 microns and a solid pharmaceutically acceptable water-soluble carrier having an effective particle size in the range 30-80 microns. The composition is preferably substantially free of particles having effective particle sizes in the range 11-29 microns. The medicament may be diluted with a solid pharmaceutically acceptable watersoluble diluent of the same effective particle size. The diluent or carrier may be dextran, mannitol or lactose preferably crystalline lactose. The medicament may be an antianaphylactic agent such as sodium chromoglycate, a sympathomimetic amine such as isoprenaline or ephedrine, an antibiotic such as penicillin or tetracycline, a steroid, enzyme, vitamin, antihistamine or mucolytic such as N- acetyl cysteine. A preferred composition contains sodium chromoglycate and isoprenaline sulphate. The surface characteristics of the medicament or carrier particles may have been modified by crystallisations, spray drying, precipitation or by coating with a pharmaceutically acceptable material, e.g. stearic acid or polyvinyl pyrrolidone (which coating may give the medicament sustained release action). The powder may be contained in a capsule, e.g. of gelatin or plastic, which is pierced for administration. The powder may be administered as a dispersion in an air stream obtained by simultaneous rotation and vibration of the pierced capsule. The composiitons are prepared by mixing together, preferably in a stirred mixer, the medicament and carrier, which if necessary have been subjected to comminution and particle size classification prior to mixing.
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB36270/67A GB1242211A (en) | 1967-08-08 | 1967-08-08 | Pharmaceutical composition |
| IE898/68A IE32343B1 (en) | 1967-08-08 | 1968-07-25 | Pharmaceutical composition |
| IE163/73A IE32872B1 (en) | 1967-08-08 | 1968-07-25 | Drug for use in pharmaceutical composition |
| FI682158A FI48973C (en) | 1967-08-08 | 1968-07-30 | A method of making a readily fluidizable inhalant. |
| US748937A US3634582A (en) | 1967-08-08 | 1968-07-31 | Pharmaceutical compositions |
| BE718846D BE718846A (en) | 1967-08-08 | 1968-07-31 | |
| CA026,437A CA946280A (en) | 1967-08-08 | 1968-08-01 | Inhalant powder compositions |
| NL6811060.A NL161984C (en) | 1967-08-08 | 1968-08-02 | METHOD FOR PREPARING A PHARMACEUTICAL POWDER-INHALED PREPARATION, AND CONTAINER CONTAINING SUCH A PREPARATION |
| DE1792207A DE1792207C3 (en) | 1967-08-08 | 1968-08-03 | Powder preparation for inhalation |
| DE19681792799 DE1792799A1 (en) | 1967-08-08 | 1968-08-03 | PHARMACEUTICAL PREPARATIONS |
| SE6810634A SE372420B (en) | 1967-08-08 | 1968-08-07 | |
| FR162134A FR8142M (en) | 1967-08-08 | 1968-08-07 | |
| NO03102/68A NO128307B (en) | 1967-08-08 | 1968-08-07 | |
| DK380968AA DK123276B (en) | 1967-08-08 | 1968-08-07 | Process for the preparation of an easily fluidizable inhalant. |
| FR163601A FR1605538A (en) | 1967-08-08 | 1968-08-21 | |
| JP2321371A JPS5643448B1 (en) | 1967-08-08 | 1971-04-14 | |
| US158059A US3860618A (en) | 1967-08-08 | 1971-06-29 | Chromone |
| US05/401,251 US3957965A (en) | 1967-08-08 | 1973-09-27 | Sodium chromoglycate inhalation medicament |
| MY330/74A MY7400330A (en) | 1967-08-08 | 1974-12-30 | Pharmaceutical composition |
| MY329/74A MY7400329A (en) | 1967-08-08 | 1974-12-30 | Drug for use in pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB36270/67A GB1242211A (en) | 1967-08-08 | 1967-08-08 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1242211A true GB1242211A (en) | 1971-08-11 |
Family
ID=10386572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB36270/67A Expired GB1242211A (en) | 1967-08-08 | 1967-08-08 | Pharmaceutical composition |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US3634582A (en) |
| JP (1) | JPS5643448B1 (en) |
| BE (1) | BE718846A (en) |
| CA (1) | CA946280A (en) |
| DE (2) | DE1792799A1 (en) |
| DK (1) | DK123276B (en) |
| FI (1) | FI48973C (en) |
| FR (2) | FR8142M (en) |
| GB (1) | GB1242211A (en) |
| IE (1) | IE32343B1 (en) |
| MY (2) | MY7400329A (en) |
| NL (1) | NL161984C (en) |
| NO (1) | NO128307B (en) |
| SE (1) | SE372420B (en) |
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2229981A1 (en) * | 1971-06-22 | 1972-12-28 | Fisons Ltd , London | Pharmaceutical powder preparations |
| FR2481601A1 (en) * | 1980-04-30 | 1981-11-06 | Fisons Ltd | PHARMACEUTICAL MIXTURE OF 1,3-BIS- (2-CARBOXYCHROMONE-5-YL-OXY) -PROPANE-2-OL, OR ONE OF ITS SALTS, AND AT LEAST ONE BRONCHODILATOR |
| US4515805A (en) * | 1980-11-05 | 1985-05-07 | Fisons Plc | Soluble sodium cromoglycate compositions |
| US5551489A (en) * | 1993-10-01 | 1996-09-03 | Astra Aktiebolag | Agglomeration of finely divided powders |
| US6102036A (en) * | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
| US6153224A (en) * | 1995-01-31 | 2000-11-28 | Co-Ordinated Drug Development Limited | Carrier particles for use in dry powder inhalers |
| US6183782B1 (en) | 1994-03-15 | 2001-02-06 | Glaxo Group Limited | Inhalation composition containing lactose pellets |
| US6221338B1 (en) | 1993-10-26 | 2001-04-24 | Vectura Limited | Method of producing particles for use in dry powder inhalers |
| US6371171B1 (en) | 1993-10-01 | 2002-04-16 | Astra Aktiebolag | Agglomeration of finely divided powders |
| US6436902B1 (en) | 1994-12-22 | 2002-08-20 | Astrazeneca Ab | Therapeutic preparations for inhalation |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US6610653B1 (en) | 1994-06-23 | 2003-08-26 | Astrazeneca Ab | Therapeutic preparation for inhalation |
| US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| US6794357B1 (en) | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US6846801B1 (en) | 1993-06-24 | 2005-01-25 | Astrazeneca Ab | Systemic administration of a therapeutic preparation |
| US6884794B2 (en) | 2000-04-17 | 2005-04-26 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| US6932962B1 (en) | 1994-12-22 | 2005-08-23 | Astrazeneca Ab | Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides |
| US7207330B1 (en) | 1999-06-05 | 2007-04-24 | Innovata Biomed Limited | Delivery system |
| US7219665B1 (en) | 1999-09-04 | 2007-05-22 | Innovata Biomed Limited | Delivery device |
| US7399528B2 (en) | 1999-07-16 | 2008-07-15 | Chiesi Farmaceutici S.P.A. | Powder particles with smooth surface for use in inhalation therapy |
| US7464704B2 (en) | 2001-11-23 | 2008-12-16 | Innovata Biomed Limited | Medicament delivery assembly |
| US7541022B2 (en) | 2000-04-17 | 2009-06-02 | Vectura Limited | Pharmaceutical formulations for dry powder inhalers |
| US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
| US8236979B2 (en) | 2008-07-24 | 2012-08-07 | American Air Liquide, Inc. | Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors |
| WO2013104892A1 (en) | 2012-01-13 | 2013-07-18 | Hovione Inter Limited | Application of high dose compounds via inhalation |
| US8511302B2 (en) | 2004-04-24 | 2013-08-20 | Innovata Biomed Limited | Dose counter mechanisms for medicament delivery devices |
| US8851069B2 (en) | 2004-04-21 | 2014-10-07 | Innovata Biomed Limited | Inhaler |
| US9987229B2 (en) | 2003-09-02 | 2018-06-05 | Norton Healthcare Ltd. | Process for preparing a medicament |
| WO2020031119A1 (en) | 2018-08-07 | 2020-02-13 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
| US11090294B2 (en) | 2009-12-01 | 2021-08-17 | Glaxo Group Limited | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
| US11116721B2 (en) | 2009-02-26 | 2021-09-14 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
| EP4316473A2 (en) | 2013-03-28 | 2024-02-07 | Vectura Limited | Use of stearate in an inhalable formulation |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787100A (en) * | 1971-08-06 | 1973-02-02 | Beecham Group Ltd | COMPOSITION FOR THE TREATMENT OF ASTHMA |
| GB1410588A (en) * | 1971-08-10 | 1975-10-22 | Fisons Ltd | Composition |
| DE2332663C2 (en) * | 1973-06-23 | 1986-07-31 | Schering AG, 1000 Berlin und 4709 Bergkamen | Use of corticosteroid active ingredients for inhalation therapy |
| DE2535258C2 (en) * | 1974-08-10 | 1993-06-03 | Fisons Plc, Ipswich, Suffolk | Inhalable drug in pellet form |
| US4161516A (en) * | 1975-07-25 | 1979-07-17 | Fisons Limited | Composition for treating airway disease |
| IL51314A (en) * | 1976-01-30 | 1980-03-31 | Fisons Ltd | Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it |
| JPS59163313A (en) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | Peptide hormone composition for nasal administration |
| US5204113A (en) * | 1987-04-09 | 1993-04-20 | Fisons Plc | Pharmaceutical compositions containing pentamidine |
| JP2770970B2 (en) * | 1987-04-09 | 1998-07-02 | フアイソンズ・ピーエルシー | Pharmaceutical composition containing pentamidine |
| DE4140689B4 (en) * | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalable powders and process for their preparation |
| CA2115444C (en) * | 1992-06-12 | 2000-10-03 | Yuji Makino | Preparation for intratracheobronchial administration |
| NL9301851A (en) * | 1993-10-26 | 1995-05-16 | Cordis Europ | Cryo-ablation catheter. |
| DE4425255A1 (en) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulation for inhalation application |
| US6648848B1 (en) * | 1997-05-27 | 2003-11-18 | Direct-Haler A/S | Inhaler for powdered medicaments |
| HRP20010119B1 (en) * | 1998-08-18 | 2008-05-31 | The Regents Of The University Of California | PREVENTION OF SLAUGHTERS IN THE AIRWAYS USED BY EGF-R ANTAGONISTS |
| US7354894B2 (en) * | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| EP1129705A1 (en) * | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
| MXPA02005666A (en) * | 2000-10-12 | 2002-11-29 | Boehringer Ingelheim Pharma | Novel tiotropium-containing inhalation powder. |
| UA75375C2 (en) | 2000-10-12 | 2006-04-17 | Boehringer Ingelheim Pharma | Method for producing powdery preparations for inhaling |
| US20060194773A1 (en) * | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
| DE10141377A1 (en) * | 2001-08-23 | 2003-03-13 | Boehringer Ingelheim Pharma | Scattering process for the production of powder formulations |
| US8337816B2 (en) * | 2001-09-17 | 2012-12-25 | Glaxo Group Limited | Dry powder medicament formulations |
| MXPA04004726A (en) * | 2001-11-19 | 2004-07-30 | Becton Dickinson Co | Pharmaceutical compositions in particulate form. |
| US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
| US20040014679A1 (en) * | 2002-02-20 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof |
| DE10207026A1 (en) * | 2002-02-20 | 2003-08-28 | Boehringer Ingelheim Kg | Stable inhalable powder of the calcitonin gene-related peptide antagonist, BIBN4096, useful for treating migraine, in the form of spherical nano-structured particles obtained by spray-drying |
| JP2006516531A (en) * | 2002-08-21 | 2006-07-06 | ノートン ヘルスケアー リミテッド | Inhalation composition |
| DE10255387A1 (en) * | 2002-11-28 | 2004-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New tiotropium-containing powder formulation for inhalation |
| DE10317461A1 (en) | 2003-04-16 | 2004-10-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt |
| DE10338402A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried, amorphous BIBN 4096, process for its preparation and its use as inhalant |
| US20050043247A1 (en) * | 2003-08-18 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative |
| DE10338399A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Microparticles containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine, process for their preparation and their use as inhalation powder |
| DE10338403A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant |
| US20050042178A1 (en) * | 2003-08-18 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder |
| US20050042179A1 (en) * | 2003-08-18 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine |
| DE10338407A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New inhalable powders containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine |
| TW200524577A (en) | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| PE20060259A1 (en) | 2004-04-27 | 2006-03-25 | Glaxo Group Ltd | QUINUCLIDINE COMPOUNDS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR |
| US7727962B2 (en) * | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
| US7611709B2 (en) * | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
| US7723306B2 (en) * | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
| DE102004048389A1 (en) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Modification of surfaces of lactose as adjuvant for use with powder inhalants |
| DE102004048390A1 (en) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New powder inhalants based on modified lactose mixtures as adjuvant |
| EP3199164B1 (en) | 2005-02-10 | 2020-03-18 | Glaxo Group Limited | Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| WO2014007773A1 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions comprising muscarinic receptor antagonist and sorbitol |
| US20150174064A1 (en) * | 2012-07-05 | 2015-06-25 | Arven IIac Sanayi Ve Ticaret A.S. | Compositions comprising muscarinic receptor antagonist and glucose anhydrous |
| US10111957B2 (en) | 2012-07-05 | 2018-10-30 | Arven Ilac Snayi ve Ticaret A.S. | Inhalation compositions comprising glucose anhydrous |
| WO2014007771A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising muscarinic receptor antagonist |
| CA3111941A1 (en) | 2012-10-25 | 2014-05-01 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| JP6529012B2 (en) | 2013-10-08 | 2019-06-12 | エイアイ・セラピューティクス・インコーポレーテッド | Rapamycin for the treatment of lymphangiyomyomatosis |
| JP2016534063A (en) * | 2013-10-22 | 2016-11-04 | ザ ジェネラル ホスピタル コーポレイション | Cromolyn derivatives and related imaging and treatment methods |
| EP3125875B1 (en) | 2014-04-04 | 2023-06-07 | AI Therapeutics, Inc. | An inhalable rapamycin formulation for treating age-related conditions |
| CA2963085C (en) | 2014-10-07 | 2023-02-21 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| JP2019524865A (en) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | Macrophages / microglia in neuroinflammation associated with neurodegenerative diseases |
| KR20200023285A (en) * | 2017-06-28 | 2020-03-04 | 필립모리스 프로덕츠 에스.에이. | Container with particles for use with inhaler |
| KR20210070232A (en) | 2017-07-20 | 2021-06-14 | 아즈테라피즈 인코포레이티드 | Powdered Formulation of Cromolin Sodium and Ibuprofen |
| KR20210071943A (en) | 2018-07-02 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | Powdered Formulation of Cromolin Sodium and α-Lactose |
| AU2019397436A1 (en) | 2018-12-10 | 2021-07-22 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| WO2021207060A1 (en) | 2020-04-06 | 2021-10-14 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| US20230310363A1 (en) | 2020-08-28 | 2023-10-05 | Universität Linz | Use of leoligin in the prevention of tissue damage |
| WO2026002967A1 (en) | 2024-06-24 | 2026-01-02 | Universität Linz | Leoligin and derivatives thereof as calcium channel blockers for the prevention and/or treatment of related diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1792207U (en) | 1959-04-14 | 1959-07-16 | Esslinger Sack Und Planenfabri | TRANSPORTABLE GARDEN SWIMMING POOL OR POOL WITH WALLS MADE OF PLASTIC FOIL. |
| FR1489749A (en) | 1965-03-25 | 1967-07-28 | Fisons Pharmaceuticals Ltd | Process for the preparation of bis-chromonyl compounds and their derivatives |
-
1967
- 1967-08-08 GB GB36270/67A patent/GB1242211A/en not_active Expired
-
1968
- 1968-07-25 IE IE898/68A patent/IE32343B1/en unknown
- 1968-07-30 FI FI682158A patent/FI48973C/en active
- 1968-07-31 US US748937A patent/US3634582A/en not_active Expired - Lifetime
- 1968-07-31 BE BE718846D patent/BE718846A/xx not_active IP Right Cessation
- 1968-08-01 CA CA026,437A patent/CA946280A/en not_active Expired
- 1968-08-02 NL NL6811060.A patent/NL161984C/en not_active IP Right Cessation
- 1968-08-03 DE DE19681792799 patent/DE1792799A1/en not_active Ceased
- 1968-08-03 DE DE1792207A patent/DE1792207C3/en not_active Expired
- 1968-08-07 DK DK380968AA patent/DK123276B/en unknown
- 1968-08-07 FR FR162134A patent/FR8142M/fr not_active Expired
- 1968-08-07 SE SE6810634A patent/SE372420B/xx unknown
- 1968-08-07 NO NO03102/68A patent/NO128307B/no unknown
- 1968-08-21 FR FR163601A patent/FR1605538A/fr not_active Expired
-
1971
- 1971-04-14 JP JP2321371A patent/JPS5643448B1/ja active Pending
-
1974
- 1974-12-30 MY MY329/74A patent/MY7400329A/en unknown
- 1974-12-30 MY MY330/74A patent/MY7400330A/en unknown
Cited By (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2229981A1 (en) * | 1971-06-22 | 1972-12-28 | Fisons Ltd , London | Pharmaceutical powder preparations |
| FR2481601A1 (en) * | 1980-04-30 | 1981-11-06 | Fisons Ltd | PHARMACEUTICAL MIXTURE OF 1,3-BIS- (2-CARBOXYCHROMONE-5-YL-OXY) -PROPANE-2-OL, OR ONE OF ITS SALTS, AND AT LEAST ONE BRONCHODILATOR |
| US4515805A (en) * | 1980-11-05 | 1985-05-07 | Fisons Plc | Soluble sodium cromoglycate compositions |
| US6794357B1 (en) | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US6846801B1 (en) | 1993-06-24 | 2005-01-25 | Astrazeneca Ab | Systemic administration of a therapeutic preparation |
| US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| US6371171B1 (en) | 1993-10-01 | 2002-04-16 | Astra Aktiebolag | Agglomeration of finely divided powders |
| US5551489A (en) * | 1993-10-01 | 1996-09-03 | Astra Aktiebolag | Agglomeration of finely divided powders |
| US8137657B2 (en) | 1993-10-26 | 2012-03-20 | Vectura Limited | Carrier particles for use in dry powder inhalers |
| US6221338B1 (en) | 1993-10-26 | 2001-04-24 | Vectura Limited | Method of producing particles for use in dry powder inhalers |
| US6582678B2 (en) | 1993-10-26 | 2003-06-24 | Vectura Limited | Carrier particles for use in dry powder inhalers |
| US6183782B1 (en) | 1994-03-15 | 2001-02-06 | Glaxo Group Limited | Inhalation composition containing lactose pellets |
| US6955824B1 (en) | 1994-03-15 | 2005-10-18 | Glaxo Group Limited | Inhalation composition containing lactose pellets |
| US6102036A (en) * | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
| US6610653B1 (en) | 1994-06-23 | 2003-08-26 | Astrazeneca Ab | Therapeutic preparation for inhalation |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US6436902B1 (en) | 1994-12-22 | 2002-08-20 | Astrazeneca Ab | Therapeutic preparations for inhalation |
| US6932962B1 (en) | 1994-12-22 | 2005-08-23 | Astrazeneca Ab | Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides |
| US8920781B2 (en) | 1995-01-31 | 2014-12-30 | Vectura Limited | Carrier particles for use in dry powder inhalers |
| US6153224A (en) * | 1995-01-31 | 2000-11-28 | Co-Ordinated Drug Development Limited | Carrier particles for use in dry powder inhalers |
| EP1666023A2 (en) | 1995-01-31 | 2006-06-07 | Vectura Limited | Improvements in and relating to carrier particles for use in dry powder inhalers |
| EP2258342A3 (en) * | 1995-01-31 | 2014-01-08 | Vectura Limited | Improvements in and relating to carrier particles for use in dry powder inhalers |
| EP1666023B1 (en) * | 1995-01-31 | 2011-10-05 | Vectura Limited | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US7718163B2 (en) | 1995-01-31 | 2010-05-18 | Vectura Limited (01696917) | Carrier particles for use in dry powder inhalers |
| US7011818B2 (en) | 1995-01-31 | 2006-03-14 | Vectura Limited | Carrier particles for use in dry powder inhalers |
| EP2213279A3 (en) * | 1995-01-31 | 2010-10-13 | Vectura Limited | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US7207330B1 (en) | 1999-06-05 | 2007-04-24 | Innovata Biomed Limited | Delivery system |
| US7399528B2 (en) | 1999-07-16 | 2008-07-15 | Chiesi Farmaceutici S.P.A. | Powder particles with smooth surface for use in inhalation therapy |
| US7571724B2 (en) | 1999-09-04 | 2009-08-11 | Innovata Biomed Limited | Delivery device |
| US7571723B2 (en) | 1999-09-04 | 2009-08-11 | Innovata Biomed Limited | Delivery device |
| US8205614B2 (en) | 1999-09-04 | 2012-06-26 | Innovata Biomed Limited | Delivery device |
| US7219665B1 (en) | 1999-09-04 | 2007-05-22 | Innovata Biomed Limited | Delivery device |
| US7541022B2 (en) | 2000-04-17 | 2009-06-02 | Vectura Limited | Pharmaceutical formulations for dry powder inhalers |
| US8871274B2 (en) | 2000-04-17 | 2014-10-28 | Vectura Limited | Pharmaceutical formulations for dry powder inhalers |
| US7223748B2 (en) | 2000-04-17 | 2007-05-29 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| US9566239B2 (en) | 2000-04-17 | 2017-02-14 | Vectura Limited | Pharmaceutical formulations for dry powder inhalers |
| US6884794B2 (en) | 2000-04-17 | 2005-04-26 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| EP1719505A2 (en) | 2000-04-17 | 2006-11-08 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical formulations for dry powder inhalers in the form of hard pellets |
| EP2272508A2 (en) | 2000-04-17 | 2011-01-12 | Vectura Limited | Pharmaceutical Formulations for Dry Powder Inhalers |
| US7464704B2 (en) | 2001-11-23 | 2008-12-16 | Innovata Biomed Limited | Medicament delivery assembly |
| US8800550B2 (en) | 2001-11-23 | 2014-08-12 | Innovata Biomed Limited | Medicament delivery assembly |
| US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
| US9987229B2 (en) | 2003-09-02 | 2018-06-05 | Norton Healthcare Ltd. | Process for preparing a medicament |
| US8851069B2 (en) | 2004-04-21 | 2014-10-07 | Innovata Biomed Limited | Inhaler |
| US8511302B2 (en) | 2004-04-24 | 2013-08-20 | Innovata Biomed Limited | Dose counter mechanisms for medicament delivery devices |
| US8236979B2 (en) | 2008-07-24 | 2012-08-07 | American Air Liquide, Inc. | Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors |
| US11116721B2 (en) | 2009-02-26 | 2021-09-14 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
| US11090294B2 (en) | 2009-12-01 | 2021-08-17 | Glaxo Group Limited | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
| US12396986B2 (en) | 2009-12-01 | 2025-08-26 | Glaxo Group Limited | Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist |
| WO2013104892A1 (en) | 2012-01-13 | 2013-07-18 | Hovione Inter Limited | Application of high dose compounds via inhalation |
| EP4316473A2 (en) | 2013-03-28 | 2024-02-07 | Vectura Limited | Use of stearate in an inhalable formulation |
| EP4360626A2 (en) | 2013-03-28 | 2024-05-01 | Vectura Limited | Use of stearate in an inhalable formulation |
| WO2020031119A1 (en) | 2018-08-07 | 2020-02-13 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
| EP3910324A1 (en) | 2018-08-07 | 2021-11-17 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5643448B1 (en) | 1981-10-13 |
| BE718846A (en) | 1969-01-31 |
| NL161984C (en) | 1980-04-15 |
| CA946280A (en) | 1974-04-30 |
| NL6811060A (en) | 1969-02-11 |
| FR1605538A (en) | 1979-02-23 |
| NL161984B (en) | 1979-11-15 |
| MY7400330A (en) | 1974-12-31 |
| US3634582A (en) | 1972-01-11 |
| SE372420B (en) | 1974-12-23 |
| DE1792799A1 (en) | 1977-08-11 |
| FI48973B (en) | 1974-12-02 |
| IE32343L (en) | 1969-02-08 |
| NO128307B (en) | 1973-10-29 |
| IE32343B1 (en) | 1973-06-27 |
| DK123276B (en) | 1972-06-05 |
| DE1792207B2 (en) | 1977-10-13 |
| DE1792207A1 (en) | 1971-11-04 |
| DE1792207C3 (en) | 1978-06-29 |
| MY7400329A (en) | 1974-12-31 |
| FR8142M (en) | 1970-08-17 |
| FI48973C (en) | 1975-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1242211A (en) | Pharmaceutical composition | |
| JP2974409B2 (en) | Particulate drug composition | |
| US5547683A (en) | Method for producing microgranulated particle | |
| EP0322137B1 (en) | Spray dried ibuprofen | |
| US3882228A (en) | Analgesic formulations | |
| US4757090A (en) | Direct tableting acetaminophen compositions | |
| GB1381872A (en) | Pharmaceutical compositions for inhalation | |
| KR840000226A (en) | Manufacturing method of new type of medicine | |
| CA2125685A1 (en) | Powders for inhalation and process for preparing them | |
| DE69428442D1 (en) | INHALATION PREPARATIONS | |
| NO20001670L (en) | Process for the preparation of a flavor-masked pharmaceutical composition and flavor-masked pharmaceutical composition prepared in accordance with this process, as well as flavor-masked chewable tablets. | |
| EP1036562A1 (en) | Soft-pellet drug and process for the preparation thereof | |
| CA2430318A1 (en) | Powder formulation and method for producing the same | |
| US6391340B1 (en) | Dry powder pharmaceutical formulation | |
| GB934089A (en) | Improvements in or relating to sustained release medicaments | |
| KR20000070189A (en) | New Formulation for Inhalation Having a Poured Bulk Density of from 0.28 to 0.38 g/㎖, Comprising Terbutaline Sulphate, a Process for Preparing the Formulation and the Use Thereof | |
| JPH0399014A (en) | Riboflavin granule containing no auxiliaries | |
| JPH0461853B2 (en) | ||
| GB644081A (en) | Improvements in pectin products and the process of making same | |
| JPH0967247A (en) | Method for producing uniform fine particle formulation | |
| GB1511852A (en) | Reconstitutable powders | |
| GB1468815A (en) | Pharmaceutical compositions | |
| JP5034226B2 (en) | Solid formulation with stabilized ingredients | |
| CA2313629C (en) | Method for transferring one or more active ingredients between different phase carriers | |
| ES413624A3 (en) | A method for preparing a phymaceutical composition in easy fluidizable powder, specially intended for the treatment by inhalation of allergic diseases of the respiratory tract. (Machine-translation by Google Translate, not legally binding) |